The at-home kits were divvied up and picked up by 19 different school districts in Erie County for distribution.
A TRUSTED PARTNER IN
Access Bio’s mission is to improve the lives and well-being of people around the world. Through the development of in vitro diagnostics technology, Access Bio has successfully commercialized the highest quality products to battle malaria and other serious diseases.
We are a trusted partner to international public health agencies and organizations, including the World Health Organization, the Bill and Melinda Gates Foundation, UNICEF, and many others.
LEADING THE FIGHT
A challenge as complex as the Covid-19 pandemic requires
innovative, adaptable solutions. To meet the need for accurate,
reliable screening, we have a suite of products that includes
PCR, serology, and antigen testing.
Based on sequence analysis and Omicron recombinant protein test, Omicron variant does not have influence on the target region of CareStart™ COVID-19 Rapid and PCR Tests.
In accordance with Article 16 (1) of the “Korean Depository Receipt Agreement” signed between Access Bio and Korea Securities Depository on March 11, 2013, the Record Date for determining shareholders in 2020 is December 31, 2020.
Major supply chain agreements will ensure broad access to rapid testing solutions for patients and healthcare providers across US
Emergency Use Authorization Granted for CareStartTM Point-Of-Care Kit
Global Leader in Infectious Disease Diagnosis Receives FDA EUA for Serology Test Capable of Determining Subjects’ past COVID-19 Exposure and Immunoresponse within 10 Minutes
Global Leader in Infectious Disease Diagnosis Receives FDA EUA for Molecular Test that May Provide Laboratories Results in 83 Minutes or Less
Access Bio was founded on the basic principle of cherishing life and health for all people. The company has emerged as a leader in the diagnosis of infectious diseases. Although it provides a comprehensive portfolio, Access Bio is known for its work against malaria, HIV, HPV, and now, COVID-19.
Malaria and its effects are primarily concentrated in poor, developing nations. in 2018, there were an estimated 228 million cases around the world and more than 400,000 deaths. Of those, more than 90% of cases and mortalities occurred in the sub-Saharan region of Africa, and children under the age of 5 account for two-thirds of all malaria deaths worldwide.
New rapid diagnostic test now available to research organizations for low parasitemia settings
GET IN TOUCH
US HERE AND
WE’LL BE TOUCH
We are always seeking to collaborate with forward-thinking individuals, organizations, and institutions.